The consideration of life expectancy (LE) in clinical decision-making for the treatment of oncological diseases is essential. LE estimations are even more important in settings, where the disease is considered to show low aggressiveness and low cancer-specific mortality. For our analyses, we, therefore, focused on T1aN0M0 renal cell cancer (RCC) patients, where curative management options such as radical nephrectomy (RN) or partial nephrectomy (PN) were performed.